Drugs

Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492

Photo from Vasileios Askoxylakis/LinkedIn

Apr 12, 2024, 11:49

Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492

Vasileios Askoxylakis, Vice President, Global Head Oncology Early Clinical Development at Servier, shared on LinkedIn:

“Very excited to see clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492 presented for the first time at AACR24. I had the honor and privilege to work with an amazing team and lead the IND and the first-in-human clinical trial of JBH492 during my tenure as Clinical Program Leader at Novartis Institutes for Biomedical Research. Congratulations to my colleagues and friends at Novartis!”

Source: Vasileios Askoxylakis/LinkedIn

AACR24 cancer CCR7 targeting antibody-drug clinical data Clinical Program Leader first-in-human clinical trial JBH492 Novartis Novartis Institutes for Biomedical Research OncoDaily Oncology Vasileios Askoxylakis

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage